Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaadvancedresearchcompany

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Buy Sun Pharma Advanced Research Company: Sudarshan Sukhani

      Buy Sun Pharma Advanced Research Company: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one can buy Sun Pharma Advanced Research Company.

    • Top buzzing midcap stocks to trade on May 5

      Top buzzing midcap stocks to trade on May 5

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have NIIT Tech, SKS Microfinance, Dabur, Mangalam Cement, Ashapura Intimates, Future Retail DVR, Pantaloons Fashion and SPARC.

    • Sun Pharma Advanced conviction bet: Mehraboon Irani

      Sun Pharma Advanced conviction bet: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that Sun Pharma Advanced Research Company is a conviction bet and feels that Sun Pharma may give 15-20 percent return in the next one year.

    • Buy Sun Pharma Advanced: Mehraboon Irani

      Buy Sun Pharma Advanced: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that one may buy Sun Pharma Advanced Research Company.

    • Hold Sun Pharma Advanced Research Company: Sameet Chavan

      Hold Sun Pharma Advanced Research Company: Sameet Chavan

      Sameet Chavan of Angel Broking recommends holding Sun Pharma Advanced Research Company with a target of Rs 570-580.

    • Exit Sun Pharma Advanced Research: Kunal Bothra

      Exit Sun Pharma Advanced Research: Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that one may exit Sun Pharma Advanced Research Company.

    • Your Stocks: Buy/sell ideas by market experts

      Your Stocks: Buy/sell ideas by market experts

      Watch the interview of Kunal Bothra of LKP Securities to answer all the stock queries and Kalpesh Ashar of Full Circle Financial Planners and Advisors is our personal finance expert.

    • Prefer Sun Pharma: Mehraboon Irani

      Prefer Sun Pharma: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that one may prefer Sun Pharma. "One may look at Sun Pharma Advanced Research Company," he added.

    • Buy Sun Pharma Advanced Research Company: Prakash Diwan

      Buy Sun Pharma Advanced Research Company: Prakash Diwan

      Prakash Diwan of Altamount Capital Management recommends buying Sun Pharma Advanced Research Company.

    • Book some profits in Sun Pharma Adv: Gaurav Bissa

      Book some profits in Sun Pharma Adv: Gaurav Bissa

      Gaurav Bissa of LKP Securities is of the view that one can book some profits in Sun Pharma Advanced Research Company.

    • Hold Sun Pharma Advanced Research Company: Gaurav Bissa

      Hold Sun Pharma Advanced Research Company: Gaurav Bissa

      Gaurav Bissa of LKP Securities recommends holding Sun Pharma Advanced Research Company with a target of rs 210-215.

    • Stay invested in SPARC, says Kunal Bothra

      Stay invested in SPARC, says Kunal Bothra

      According to Kunal Bothra of LKP Securities, one may stay invested in Sun Pharma Advanced Research Company.

    • Bull's Eye: Buy LIC Housing, Sintex, DCB Bank, Petronet LNG

      Bull's Eye: Buy LIC Housing, Sintex, DCB Bank, Petronet LNG

      Dharmesh Kant of India Nivesh Securities recommends buying Capital First with a target at Rs 370 and DCB Bank with a target at Rs 120.

    • Buy Whirlpool, Bharat Forge, Sun Pharma Adv: Rajat Bose

      Buy Whirlpool, Bharat Forge, Sun Pharma Adv: Rajat Bose

      Rajat Bose of rajatbose.com recommends buying Whirlpool India, Bharat Forge and Sun Pharma Advanced Research Company.

    • Buy Sun Pharma Adv Research Company: Sudarshan Sukhani

      Buy Sun Pharma Adv Research Company: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Sun Pharma Advanced Research Company and advises holding the stock for a few months.

    • Buy Sun Pharma Advanced: Mehraboon Irani

      Buy Sun Pharma Advanced: Mehraboon Irani

      Mehraboon Irani, Principal and Head- Pvt Client Group Business at Nirmal Bang Securities is of the view that one can buy Sun Pharma Advanced Research Company.

    • Bull's Eye: Buy Arvind, SPARC, Indiabulls Real, Titan

      Bull's Eye: Buy Arvind, SPARC, Indiabulls Real, Titan

      Kunal Saraogi, Equityrush advises buying JSW Energy for a target price of Rs 53 and BPCL for a target price of Rs 390.

    • Bull's Eye: Buy Siemens, MphasiS, Financial Tech, KPIT Tech

      Bull's Eye: Buy Siemens, MphasiS, Financial Tech, KPIT Tech

      Lancelot D Cunha, ITI Wealth Management advises buying IndusInd Bank for a target price of Rs 394 and Crompton Greaves for a target price of Rs 125.50.

    • Buy Voltas, JK Tyre, Sun Pharma Adv, Arvind: Sharmila Joshi

      Buy Voltas, JK Tyre, Sun Pharma Adv, Arvind: Sharmila Joshi

      Sharmila Joshi of sharmilajoshi.com recommends buying Arvind with a day target of Rs 157.50 and Sun Pharma Advanced Research Company with a target of Rs 174.

    • Bull's Eye: Buy Voltas, Sun Pharma, Dish TV, Sintex

      Bull's Eye: Buy Voltas, Sun Pharma, Dish TV, Sintex

      Nooresh Mirani of Analyse India advises buying Sun Pharma for a target price of Rs 620 and Jyoti Structures for a target price of Rs 35.

    • Buy Sun Pharma Adv, BGR Energy, Rallis India: Subramanium

      Buy Sun Pharma Adv, BGR Energy, Rallis India: Subramanium

      Krish Subramanium of Asit C Mehta recommends buying BGR Energy Systems for a target of Rs 118 and Rallis India for a target of Rs 187.

    • Bull's Eye: Buy Siemens, Tata Global, BGR Energy, UPL

      Bull's Eye: Buy Siemens, Tata Global, BGR Energy, UPL

      Nooresh Merani of AMSEC Research advises buying Tata Global Beverage for a target price of Rs 155 and Godrej Industries for a target price of Rs 290.

    • Buy Sun Pharma Advanced, sell LIC Housing: Subramanium

      Buy Sun Pharma Advanced, sell LIC Housing: Subramanium

      Krish Subramanium of Asit C Mehta recommends buying Sun Pharma Advanced Research Company with a target of Rs 156 and advises selling LIC Housing Finance for a possible target of Rs 193.

    • Bull's Eye: Buy Rallis, Biocon, HDIL, Idea Cellular

      Bull's Eye: Buy Rallis, Biocon, HDIL, Idea Cellular

      Nooresh Merani of AMSEC Research recommends buying Rallis India with a target of Rs 185 and Biocon with a target of Rs 400.

    • Buy Voltas, Rallis, PTC India, Sun Pharma Adv: Merani

      Buy Voltas, Rallis, PTC India, Sun Pharma Adv: Merani

      Nooresh Merani of AMSEC Research recommends buying Voltas with a stoploss of Rs 90 and Rallis India with a target of Rs 185.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347